Traded

Crown Equity Holdings, Inc. (OTCBB:CRWE) recently reported its financial information for the 6-month period ending on June 30, 2010. Revenue for the six month period came to a total of $678,988 which was $84,357 during the same period in 2009. Also the company incurred an operating loss of $26,739 compared to an operating loss of $245,796 during the same period of 2009.

Crown Equity Holdings, Inc. has also increased its workforce to an amount of 35, compared to this time last year’s head count of 6, which is a 580% personnel increase. This is in addition to the 10 contractors we recently hired in Pakistan.

CRWE is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea’s most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

Chelsea Therapeutics has recently reported that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

CFS is a complex and crippling disorder characterized by extreme fatigue that is not improved by rest. In addition to fatigue, patients with CFS experience symptoms, similar to that of fibromyalgia including, weakness, muscle pain, impaired memory and concentration. Droxidopa has been shown to improve symptoms of fatigue, weakness and concentration in neurogenic orthostatic hypotension associated with a variety of conditions including Parkinson’s disease, multiple system atrophy and pure autonomic failure. Droxidopa is also being studied in an ongoing Phase II trial in fibromyalgia where, during an interim analysis, an independent data monitoring committee saw meaningful efficacy in multiple treatment arms.

Salesforce.com (NYSE: CRM)

Salesforce.com is the enterprise cloud computing company. Based on salesforce.com’s real-time, multitenant architecture, the company’s platform and CRM applications have revolutionized the way companies collaborate and communicate with their customers.

Salesforce.com , the enterprise cloud computing company, today announced results for its fiscal second quarter ended July 31, 2010.

“We’re delighted today to raise our full fiscal year 2011 revenue guidance to a range of $1.595 billion to $1.6 billion,” said Marc Benioff, chairman and CEO, salesforce.com. “Our accelerating revenue growth in the second quarter, combined with an excellent quarter of new business worldwide, gives us confidence to raise our guidance to this exciting new milestone.”

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.

Proteonomix Inc (OTC:PROT) a company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market. Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, recently reported it’s financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of $15.0 million, compared with a net loss of $16.8 million for the same period last year. At June 30, 2010, the Company had cash, cash equivalents, and marketable securities of $68.7 million, compared with $95.7 million at December 31, 2009. Revenue for the second quarter of 2010 was $2.8 million, compared to $6.6 million for the same period last year. The decrease in revenue was due to a decrease in reimbursable manufacturing expenses associated with our M356 program and a decrease in reimbursable expenses associated with our enoxaparin sodium injection program as the ANDA review process approached completion. Research and development expenses for the second quarter of 2010 were $11.8 million, compared to $17.7 million for the same period last year. The decrease in research and development expenses principally resulted from a decrease in manufacturing, process development and third-party research costs in support of our M356 program and clinical development costs due to the completion of our M118 Phase 2a clinical trial in June 2009.

MNTA is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has recently reported their financial results for the second quarter 2010 and presented a quarterly update on the Company’s development progress. Chelsea’s management team will host a conference call this afternoon at 4:30 PM EDT to discuss these results.

Recent Highlights:

* Reported results from Study 303 in which patients maintained statistically significant 3.2 unit improvement in orthostatic hypotension questionnaire (OHQ) composite scores following long-term NORTHERA™ (droxidopa) treatment in neurogenic orthostatic hypotension (NOH) (p<0.001);
* Initiated Northera Study 306, a pivotal Phase III trial in Parkinson’s disease patients with symptomatic neurogenic orthostatic hypotension;
* Completed enrollment in Northera Study 301, a pivotal Phase III trial in neurogenic orthostatic hypotension, bringing final enrollment to 167 patients and further increasing the power of the study to 90%;
* Reported positive interim analysis of Phase II study of droxidopa in fibromyalgia by independent data monitoring committee supporting efficacy of novel droxidopa/carbidopa combination therapy; and
* Submitted additional CH-4051 preclinical data and revised protocol for Phase II trial in rheumatoid arthritis to the U.S. Food and Drug Administration (FDA).

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea’s most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.

CRWEFinance.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From CRWEFinance.com

________________________________________

CRWEFinance.com Stock Report!

********************************************************************************

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced it has obtained commitments from institutional investors to purchase approximately $18.2 million of its common stock and warrants in a registered direct offering.

At closing, Chelsea will issue 6,700,000 million shares of its common stock at $2.72 per share along with warrants to purchase up to approximately 2.3 million additional shares of common stock. The warrants have a 3-year term and are exercisable at a price of $2.79 per share any time after the six-month anniversary of the date of issuance.

Power 3 Medical Products Inc. (PWRM.OB) announced has signed a definitive agreement to acquire all of the stock of StemTroniX Inc., a Texas corporation (”StemTroniX”). Power3 plans to effectuate the acquisition of StemTroniX by merging a wholly-owned subsidiary of the Company with and into StemTroniX. StemTroniX will remain as the surviving company in the merger and will become a wholly-owned subsidiary of Power3. The acquisition of StemTroniX is expected to be completed in April 2010.
Web Site: http://www.Power3Medical.com

***********Advertisement***********

********************************************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

CRWEFinance.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From CRWEFinance.com

________________________________________

CRWEFinance.com Stock Report!

Be sure to check out more news at crwefinance.ning.com as well.

********************************************************************************

China Digital Animation Development,Inc. (OTCBB:CHDA) has appointed Andrew Mininger to the Board of Directors, bringing the number of board members to four.

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, in combination with carbidopa has been initiated in adult attention deficit hyperactivity disorder (ADHD).

Consorteum Holdings, Inc. (OTCBB:CSRH) has previously announced that the Company has signed a management agreement with UK based Blue Sea Manning Ltd. to provide integrated payroll and multi-currency settlement solutions.

***********Advertisement***********

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand dollars from Consorteum Holdings Inc. for 30 days of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has received 78,000 free trading and 500,000 144 (restricted) shares from a third party for 6 months of advertising services Consorteum Holdings Inc, (CSRH.OB).

CRWEFinance.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From CRWEFinance.com

________________________________________

CRWEFinance.com Stock Report!

Be sure to check out more news at crwefinance.ning.com as well.

********************************************************************************

Global supercomputer leader Cray Inc. (Nasdaq:CRAY) plans to host an investor conference call on Tuesday, Feb. 16 at 1:15 p.m. PST (4:15 p.m. EST) to discuss 2009 fourth quarter and full year financial results. The call will feature a discussion by senior management followed by a Q&A session.

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced several updates related to its Phase III registration program in neurogenic orthostatic hypotension (NOH), including the selection and preliminary approval by the FDA of Northera(tm) as the U.S. brand name for Droxidopa in this indication.

Using the Company’s BC-SeraPro platform, Power3 Medical Products, Inc. (PWRM.OB) used protein biomarkers to distinguish women with breast cancer from those with benign abnormal breast conditions and with normal breasts with sensitivities and specificities in the 80%-90% range, in retrospective banked and prospective newly drawn samples from patients and controls. The biomarkers also distinguish between women with purely invasive primary breast cancer and women who also have ductal carcinoma in situ, which is often missed in mammograms.In addition, following the “Principals of Omic Medicine” that Dr. Goldknopf promoted at the international scientific meetings in the US and China, the company has disclosed methods for making biomarker specific antibodies for development of a user friendly commercial test for breast cancer.

***********Advertisement***********

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).